Octapharma to access Prometic's affinity technology

Montreal - ProMetic Life Sciences Inc. has signed a $1.4 million development agreement with Octapharma AG, a Swiss-based global plasma fractionation specialist and one of the key players in the European plasma protein market. This new collaboration agreement provides Octapharma with access to ProMetic's advanced Mimetic Ligand(TM) affinity technology which enables the cost-effective manufacture of high-purity protein drugs.

"This new partnership brings added recognition to ProMetic's expertise and further consolidates our position as a leading provider of innovative bioseparation …